27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Previous small studies and case reports have suggested that neurological disorders may be associated with bullous pemphigoid (BP). 4 key findings →
Design: case-control study Participants: 868 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease pathology (Aβ plaques, neurofibrillary tangles, and cerebral amyloid angiopathy) was significantly higher in the dMCI group than the sMCI group. 3 key findings →
Design: longitudinal study Participants: 28 Evidence: moderate
Full summary, score breakdown and related studies → Original source
People with raised systolic blood pressure (≥160 mm Hg) or high serum cholesterol concentration (≥6.5 mmol/l) in midlife had a significantly higher risk of Alzheimer's disease in later life, even after adjustment for age, body mass index, education, vascular events, smoking status, and alcohol consumption, than those with normal systolic blood pressure (odds ratio 2.3, 95% confidence interval 1.0 to 5.5) or serum cholesterol (odds ratio 2.1, 1.0 to 4.4). 5 key findings →
Participants: 1,449 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Vascular Dementia (VaD) occurs due to cerebrovascular insufficiency, which leads to decreased blood circulation to the brain, thereby resulting in mental disabilities. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Donepezil-treated patients demonstrated significant improvements in cognition and global function compared with placebo-treated patients, and donepezil was well tolerated. 5 key findings →
Participants: 616 Evidence: high
Full summary, score breakdown and related studies → Original source
Subclinical structural brain abnormalities in high-functioning older adults can increase the risk of developing physical disabilities and declining in motor performance. 1 key finding →
Design: longitudinal study Participants: 2,450 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Three survey rounds included 49 to 54 participants that agreed on VasCog-2 diagnostic criteria for preclinical, mild, and major dementia levels of vascular cognitive impairment (under the overarching term VCID). 5 key findings →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We included 147,986 participants (Chinese [n = 6,034], Filipino [n = 4,649], Japanese [n = 3,099], South Asian [n = 996], non-Latino White [n = 133,208]); the mean baseline age ranged from 69 to 72 years, and the percentage of female participants ranged from 40% to 63% across groups. 5 key findings →
Design: cohort study Participants: 6,034 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
White matter hyperintensities (WMH) - - areas of increased signal appearing on T2-weighted magnetic resonance imaging - - are associated with Alzheimer’s disease (AD) risk and progression in late onset and genetic forms. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 4712 participants (59% female; mean age, 74 years), 193 ischemic strokes and 769 dementia cases were ascertained over a median follow-up of 8.3 years. 5 key findings →
Design: cohort study Participants: 4,712 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After propensity score matching, each group consisted of 15901 patients. 5 key findings →
Design: cohort study Participants: 15,901 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 42 342 participants from the pooled cohorts were included (mean [SD] age, 61.3 [9.8] years; 55.0% female). 5 key findings →
Design: cohort study Participants: 342 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There is increasing recognition of the importance of blood-brain barrier (BBB) disruption in aging, dementia, stroke and multiple sclerosis in addition to more commonly-studied pathologies such as tumors. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
IL-6, and, to a lesser degree, CRP levels were associated with WMH severity as well as global markers of brain atrophy. 4 key findings →
Design: cross-sectional Participants: 1,316 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Clinicians accurately predicted AD pathological findings or their absence in most cases. 4 key findings →
Design: cohort study Participants: 151 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Persons with MCI also have impaired motor function, and the degree of impairment in lower extremity function is related to the risk of AD. 1 key finding →
Design: cohort study Participants: 558 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Consumption of up to three servings of wine daily is associated with a lower risk of AD in elderly individuals without the APOE epsilon-4 allele. 5 key findings →
Design: cohort study Participants: 260 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Elevated midlife blood pressures, and the resulting increased white matter hyperintensities, increase the risk for MCI in a group of community-dwelling older men to at least the same degree as apolipoprotein E4 genotype. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
We conclude that smaller PFAv may contribute to slower gait through slower information processing. 4 key findings →
Design: longitudinal study Participants: 214 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Hyperhomocysteinemia is associated with an increased risk of vascular disease, and recent results suggest that it also could increase the risk of dementia. 4 key findings →
Design: cross-sectional Participants: 1,241 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The results of this preliminary case-control study suggest that estradiol levels may decline significantly in women in whom AD develops. 5 key findings →
Design: case-control study Participants: 50 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 251 patients examined 3 months after the onset of acute ischemic stroke, we diagnosed dementia in 66 (26.3%) by using modified DSM-III-R criteria based on neuropsychological, neurological, functional, and psychiatric examinations. 4 key findings →
Design: cross-sectional Participants: 251 Evidence: low
Full summary, score breakdown and related studies → Original source
We identified 1143 dementia-free individuals with acute stroke during follow-up: 1061 (92.8%) ischemic, 82 (7.2%) hemorrhagic, 49.9% female, and 30.8% Black. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The telmisartan group had the lowest risk of all dementias (telmisartan vs NT-ARB: hazard ratio [HR]: 0.78; 95% confidence interval [CI]: 0.60 to 1.01; telmisartan vs angiotensin-converting enzyme inhibitor: HR: 0.67; 95% CI: 0.48 to 0.94). 5 key findings →
Design: cohort study Participants: 39,665 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The three year results of the LADIS study suggest that in older adults who seek medical attention for non-disabling complaints, severe age related changes in white matter independently and strongly predict rapid global functional decline. 3 key findings →
Participants: 633 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →